Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival for older AML patients better with HSCT from unrelated donors

Key clinical point: Overall survival was higher with matched unrelated vs. haploidentical donors.

Major finding: The hazard ratio for overall mortality with haploidentical donors was 1.27 (P = .04).

Study details: Retrospective study of 823 adults aged 50 and older with acute myeloid leukemia who underwent stem cell transplant in first or second remission.

Disclosures: The study was funded by grants from the National Institutes of Health and the Office of Naval Research. Dr. Tomlinson reported no relevant disclosures. Dr. Champlin did not report disclosures.

Citation:

Perales M-A et al. Haematologica. 2020 Jan 31;105(2):407-13.